The EPS projection of Bio-Techne Corp (NASDAQ:TECH) for quarter ended 2016-09-30 is $0.8. Last week, the EPS forecast was $0.8 against target of $0.8, a month earlier. Two months ago, this estimate was $0.8 versus forecast of $0.8 three months earlier, implying a deviation of 0%.
Bio-Techne Corp (NASDAQ:TECH) stated that 18 days ago, its stock price was positively revised 0 times while negative revisions were 0.
In last week, the experts lowered EPS 0 times and increased EPS 0 times. In last 30, 120, 60 and 90 days, the experts upped revisions 0 , 0, 0, and 0, correspondingly.
EPS estimate downgrade for Bio-Techne Corp (NASDAQ:TECH) in the preceding 30, 120, 60 and 90 days were 0, 0, 0, and 0, correspondingly.
Bio-Techne Corp (NASDAQ:TECH) EPS target for the quarter closed 3 was $0.8, based on 3 recommendations. As reported on 2016-05-03 the EPS was $0.97. The change was $0.12, implying a percentage deviation of 14.12%. The projections showed a standard deviation of 0.03.
Quarterly Sales Estimates
Bio-Techne Corp (NASDAQ:TECH) yearly sales prediction for the fiscal 2017 stands at $136.638 and the median estimate is at $136.78. Almost 5 analysts issued sales target.
Highest sales target is $140.4 while the lowest target is $132.53 showing standard deviation of 2.984%.
As many as 5 analysts have sales targets revised upside while 5 reduced sales estimates, implying a deviation of 0%.
Last month, 5 revised sales number projection on upside while 5 lowered the sales projections, implying a deviation of 0.123%.
A quarter ago, 5 hiked sales target and 5 reduced sales forecast. Bio-Techne Corp (NASDAQ:TECH) announced that the deviation in forecast was 1.245%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...